- $17.92m
- $21.62m
- $52.68m
Annual income statement for IRIDEX, fiscal year end - January 3rd, USD millions except per share, conversion factor applied.
2022 December 31st | 2022 January 1st | 2023 December 30th | 2024 December 28th | 2026 January 3rd | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 57 | 53.9 | 51.9 | 48.7 | 52.7 |
| Cost of Revenue | |||||
| Gross Profit | 25.4 | 22.8 | 21.8 | 19.5 | 19.2 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 64.5 | 58.9 | 61.9 | 57 | 55.2 |
| Operating Profit | -7.54 | -5.03 | -10 | -8.3 | -2.57 |
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -7.48 | -5.18 | -9.48 | -8.84 | -4.38 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -7.55 | -5.22 | -9.57 | -8.91 | -4.44 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -7.55 | -5.22 | -9.57 | -8.91 | -4.44 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -7.55 | -5.22 | -9.57 | -8.91 | -4.44 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.474 | -0.444 | -0.593 | -0.542 | -0.262 |